低危甲状腺癌的I131消融治疗.pdf

The new england journal of medicine established in 1812 may 3, 2012 vol. 366 no. 18 Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer Martin Schlumberger, M.D., Bogdan Catargi, M.D., Ph.D., Isabelle Borget, Pharm.D., Ph.D., Désirée Deandreis, M.D., Slimane Zerdoud, M.D., Boumédiène Bridji, M.D., Ph.D., Stéphane Bardet, M.D., Laurence Leenhardt, M.D., Ph.D., Delphine Bastie, M.D., Claire Schvartz, M.D., Pierre Vera, M.D., Ph.D., Olivier Morel, M.D., Danielle Benisvy, M.D., Claire Bournaud, M.D., Françoise Bonichon, M.D., Catherine Dejax, M.D., Marie-Elisabeth Toubert, M.D., Sophie Leboulleux, M.D., Marcel Ricard, Ph.D., and Ellen Benhamou, M.D., for the Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial* A bs tr ac t Background It is not clear whether the administration of radioiodine provides any benefit to The authors’ affiliations are listed in the patients with low-risk thyroid cancer after a complete surgical resection. The admin- Appendix. Address reprint requests to Dr. Schlumberger at the Service de Médecine istration of the smallest possible amount of radioiodine would improve care. Nucléaire et de Cancérologie Endocrini- enne et Université Paris Sud, Institut de Methods Cancérologie Gustave Roussy, 114 Rue In our randomized, phase 3 trial, we compared two thyrotropin